Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05726370 · ClinicalTrials.gov registry record · Phase 2

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

A Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
Phase 2
Development phase
28
Enrollment target
2
Study locations

NCT05726370 is a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 28 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05726370, a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
Phase 2
Development phase
28 participants
Enrollment target
2
Study locations

Study Summary

This research study is evaluating effectiveness and safety of a combination of immunotherapy drug, pembrolizumab, with chemotherapy, as a possible treatment before and after surgery for squamous cell carcinoma of the head and neck (HNSCC). The combination of pembrolizumab and chemotherapy will be given prior to your surgery, while immunotherapy pembrolizumab will be continued for approximately 1 year after surgery. The names of the study drugs involved in this research study are: * pembrolizumab (a type of immunotherapy) * docetaxel (a type of chemotherapy) * cisplatin (a type of chemotherapy) * carboplatin (a type of chemotherapy)

Conditions Studied

Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma Resectable Head and Neck Squamous Cell Carcinoma Second Primary Squamous Cell Carcinoma of the Head and Neck

Interventions

  • DRUG Pembrolizumab
  • DRUG Carboplatin
  • DRUG Docetaxel
  • DRUG CISPLATIN

Study Locations (2)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2023-05-20
Est. Completion 2030-05-20
Phase Phase 2

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05726370

The ClinicalTrials.gov registry entry for NCT05726370 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT05726370 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05726370 about?

NCT05726370 is a clinical study titled "Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC". This research study is evaluating effectiveness and safety of a combination of immunotherapy drug, pembrolizumab, with chemotherapy, as a possible treatment before and after surgery for squamous cell carcinoma of the head and neck (HNSCC). The combination of pembrolizumab and chemotherapy will be gi...

What is the current status of trial NCT05726370?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2023-05-20. Estimated completion is 2030-05-20.

What conditions does trial NCT05726370 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck.

What interventions are being tested in trial NCT05726370?

The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), CISPLATIN (DRUG).

Who is sponsoring clinical trial NCT05726370?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05726370 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

Head and Neck Squamous Cell Carcinoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.